Captor Therapeutics Spolka Akcyjna
CTX.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.28 | 0.52 | -0.22 | 0.24 |
| FCF Yield | -5.15% | -5.70% | 10.72% | -3.81% |
| EV / EBITDA | -21.43 | -18.25 | -21.55 | -26.47 |
| Quality | ||||
| ROIC | -30.28% | -22.77% | -17.50% | -15.05% |
| Gross Margin | 0.00% | -29.00% | 66.50% | 27.32% |
| Cash Conversion Ratio | 1.00 | 1.09 | -2.15 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -15.48% | 0.81% | 12.95% | 20.00% |
| Free Cash Flow Growth | -8.64% | -146.11% | 359.64% | -535.78% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 1.46 | 1.27 | 4.48 |
| Interest Coverage | -193.66 | -298.47 | -103.04 | -87.85 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 183.83 | -173.49 | -316.86 | 1,054.45 |